MX345056B - Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa. - Google Patents

Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa.

Info

Publication number
MX345056B
MX345056B MX2014003572A MX2014003572A MX345056B MX 345056 B MX345056 B MX 345056B MX 2014003572 A MX2014003572 A MX 2014003572A MX 2014003572 A MX2014003572 A MX 2014003572A MX 345056 B MX345056 B MX 345056B
Authority
MX
Mexico
Prior art keywords
diagnosis
treatment
fge
sulfatase deficiency
generating enzyme
Prior art date
Application number
MX2014003572A
Other languages
English (en)
Inventor
Von Figura Kurt
Schmidt Bernhard
Dierks Thomas
W Heartlein Michael
Ballabio Andrea
Pia Cosma Maria
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of MX345056B publication Critical patent/MX345056B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a se refiere a una composición que comprende iduronato 2-sulfatasa recombinante producida por células de mamífero transfectadas con un vector que comprende un polinucleótido que codifica para la iduronato 2-sulfatadas y en la cual las células de mamífero co-expresan una enzima generador de formilglicina (FGE), en donde la iduronato 2-sulfatasa tiene porcentaje de relación incrementada de iduronato 2-sulfatasa activa en comparación con una sulfatasa de control producida por las mismas células de mamífero en ausencia de la FGE.
MX2014003572A 2003-02-11 2004-02-10 Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa. MX345056B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774703P 2003-02-11 2003-02-11
PCT/US2004/003632 WO2004072275A2 (en) 2003-02-11 2004-02-10 Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)

Publications (1)

Publication Number Publication Date
MX345056B true MX345056B (es) 2017-01-16

Family

ID=32869644

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014003572A MX345056B (es) 2003-02-11 2004-02-10 Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa.
MXPA05008533A MXPA05008533A (es) 2003-02-11 2004-02-10 Diagnostico y tratamiento de deficiencia de sulfatasa multiple y otras deficiencias de sulfatasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA05008533A MXPA05008533A (es) 2003-02-11 2004-02-10 Diagnostico y tratamiento de deficiencia de sulfatasa multiple y otras deficiencias de sulfatasa.

Country Status (18)

Country Link
US (4) US8227212B2 (es)
EP (3) EP2325301B1 (es)
JP (3) JP5241101B2 (es)
CN (4) CN101444621B (es)
AT (1) ATE534730T1 (es)
AU (2) AU2004210936C1 (es)
CA (1) CA2515708A1 (es)
CY (1) CY1117346T1 (es)
DK (2) DK2325302T3 (es)
ES (3) ES2380147T3 (es)
HK (3) HK1090088A1 (es)
HU (1) HUE027210T2 (es)
MX (2) MX345056B (es)
NZ (4) NZ570201A (es)
PT (1) PT1592786E (es)
SI (1) SI2325302T1 (es)
WO (1) WO2004072275A2 (es)
ZA (1) ZA200506378B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027210T2 (en) * 2003-02-11 2016-10-28 Shire Human Genetic Therapies Cells expressing the enzyme producing sulfatase and C-formylglycine together and their uses
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP2051734B1 (en) 2006-08-18 2016-10-05 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CA3184105A1 (en) * 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
AR070198A1 (es) 2008-01-18 2010-03-17 Biomarin Pharm Inc Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos
WO2009120611A2 (en) * 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
WO2011041582A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011044542A1 (en) 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US8351868B2 (en) * 2009-11-20 2013-01-08 Motorola Solutions, Inc. Radio status indicator
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP2799862B1 (en) 2011-12-20 2017-03-08 JCR Pharmaceuticals CO., LTD. Method for analyzing formyl glycine residue
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
EA201491578A1 (ru) 2012-03-30 2015-04-30 Шир Хьюман Дженетик Терапис, Инк. Подкожное введение идуронат-2-сульфатазы
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
US20150023956A1 (en) * 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
WO2016007909A2 (en) * 2014-07-11 2016-01-14 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
JPWO2016121715A1 (ja) * 2015-01-26 2017-11-02 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
CN107250372B (zh) * 2015-02-05 2022-11-01 R.P.谢勒技术有限责任公司 活化的甲酰甘氨酸生成酶及其生成和使用方法
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
AU2017333336B2 (en) * 2016-09-30 2023-11-09 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
BR112019013202A2 (pt) 2016-12-28 2019-12-10 Japan Chem Res formulação liofilizada
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CN109628426B (zh) * 2019-01-02 2023-05-09 山东大学 一种δ4,5-己糖醛酸-2-o-硫酸酯酶及其编码基因与应用以及同类酶的鉴定方法
CN109781997A (zh) * 2019-01-22 2019-05-21 中国人民解放军总医院 用于诊断粘多糖病ⅱ型的生物标志物及其应用
JP2023521319A (ja) 2020-04-03 2023-05-24 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
AU2021252515A1 (en) * 2020-04-06 2022-10-27 Homology Medicines, Inc. Adeno-associated virus compositions for IDS gene transfer and methods of use thereof
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
JP2024519986A (ja) 2021-05-27 2024-05-21 アール．ピー．シェーラー テクノロジーズ，エルエルシー ホルミルグリシン含有ポリペプチドの切断を制御する方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3307A (en) 1843-10-18 Laben eddy
US307A (en) 1837-07-29 Rqss winans
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4748024A (en) 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
DE69531044T2 (de) * 1994-03-16 2003-12-04 The Regents Of The University Of California, Alameda Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung
US5863782A (en) * 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP1179000A4 (en) * 1999-02-26 2005-10-12 Millennium Pharm Inc DECISION PROTEINS AND THEIR USE
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
JP2002017376A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
JP2003508088A (ja) * 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
US6780627B1 (en) * 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
WO2001060991A2 (en) * 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
WO2001070804A1 (en) * 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
WO2001079480A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1397495A2 (en) 2000-12-21 2004-03-17 Millenium Pharmaceuticals, Inc. 22437, a human sulfatase and uses therefor
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
US20030147875A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003020947A2 (en) 2001-08-31 2003-03-13 Millennium Pharmaceuticals, Inc. Mid 9002, a human sulfatase family member and uses therefor
HUE027210T2 (en) * 2003-02-11 2016-10-28 Shire Human Genetic Therapies Cells expressing the enzyme producing sulfatase and C-formylglycine together and their uses
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
CN105450838B (zh) 2014-09-01 2019-12-24 联想(北京)有限公司 一种信息处理方法及电子设备

Also Published As

Publication number Publication date
US20130172403A1 (en) 2013-07-04
AU2010212261B2 (en) 2012-04-26
EP2325302A8 (en) 2012-02-22
EP2325302B1 (en) 2016-01-06
HK1090088A1 (en) 2006-12-15
JP2006517412A (ja) 2006-07-27
EP2325301A1 (en) 2011-05-25
JP6007203B2 (ja) 2016-10-12
EP2325301B1 (en) 2015-09-02
EP1592786B8 (en) 2012-03-21
HUE027210T2 (en) 2016-10-28
EP1592786A2 (en) 2005-11-09
DK1592786T3 (da) 2012-02-13
MXPA05008533A (es) 2005-10-20
AU2004210936B2 (en) 2010-05-13
US8227212B2 (en) 2012-07-24
ATE534730T1 (de) 2011-12-15
NZ596420A (en) 2012-11-30
CN103055306B (zh) 2020-10-27
ES2566641T3 (es) 2016-04-14
DK2325302T3 (en) 2016-03-14
CN110496230A (zh) 2019-11-26
CA2515708A1 (en) 2004-08-26
NZ603330A (en) 2015-02-27
CN1759176B (zh) 2012-10-03
PT1592786E (pt) 2012-01-19
HK1152336A1 (en) 2012-02-24
US20130028881A1 (en) 2013-01-31
JP2012090630A (ja) 2012-05-17
WO2004072275A2 (en) 2004-08-26
US20040229250A1 (en) 2004-11-18
EP2325302A1 (en) 2011-05-25
EP1592786B1 (en) 2011-11-23
CN103055306A (zh) 2013-04-24
ZA200506378B (en) 2006-12-27
JP5527854B2 (ja) 2014-06-25
NZ542267A (en) 2008-12-24
AU2004210936C1 (en) 2010-12-02
JP2014131515A (ja) 2014-07-17
NZ570201A (en) 2011-03-31
CY1117346T1 (el) 2017-04-26
CN101444621B (zh) 2013-11-20
AU2010212261C1 (en) 2012-12-06
AU2004210936A1 (en) 2004-08-26
JP5241101B2 (ja) 2013-07-17
CN101444621A (zh) 2009-06-03
AU2010212261A1 (en) 2010-09-02
ES2555056T3 (es) 2015-12-28
SI2325302T1 (sl) 2016-05-31
WO2004072275A3 (en) 2005-04-14
CN1759176A (zh) 2006-04-12
HK1152337A1 (zh) 2012-02-24
US20160367703A1 (en) 2016-12-22
ES2380147T3 (es) 2012-05-09

Similar Documents

Publication Publication Date Title
MX345056B (es) Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa.
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
AU2002360488A8 (en) Methods and devices for detection and therapy of atheromatous plaque
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
PT1753440E (pt) Forma de administração oral contendo bactérias probióticas
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
TW200718687A (en) Inhibitors of cytosolic phospholipase A2
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
NO20061138L (no) Gjaercellevegger for behandling eller forebygging av hyperglukemi eller for a stabilisere glukemi
NO20084821L (no) Formuleringer og metoder for celleimaging og terapi
TW200605885A (en) Multicyclic lonidamine analogs
WO2003105753A3 (en) METHODS AND COMPOSITIONS FOR GRAFTING FUNCTIONAL LOOPS INTO A PROTEIN
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
PT1814879E (pt) Derivados de 4,7-dioxobenzotiazole-2-carboxamidas, sua preparação e suas aplicações terapêuticas
AU2606000A (en) Antisense modulation of x-linked inhibitor of apoptosis expression
SI1539815T1 (sl) Kristalna struktura encima, ki pretvarja angiotenzin (ACE), in njegove uporabe
AU2003222462A1 (en) Method of performing soojichim acupuncture using bodycopy
WO2002095001A3 (en) Btf3: an inhibitor of apoptosis
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation
WO2003106645A3 (en) ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION
WO2005054174A3 (de) Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes